HIV vaccine nanoparticle avidity enhances durable immune response in preclinical studies | Drug target review
Search for HIV vaccine It became an exercise in precision engineering. Instead of simply exposing the immune system to HIV proteins in the hope that it will produce protective antibodies, researchers are designing vaccines to find rare B cells and guide them through the complex process that can eventually produce broadly neutralizing antibodies.
Now, two studies from researchers at Scripps Research, University of Texas Medical Branch and I hope She suggests that another feature of the vaccine design may be important: How powerful the vaccine nanoparticles are in engaging target B cells.
First study Find out how greed affects you Durability of the immune responsewhile the second Investigate how it affects Which immune cells are most successful during that response?.
While their findings are preclinical, they offer researchers another variable to optimize as they try to steer the immune system toward producing broadly neutralizing antibodies capable of blocking multiple strains of HIV.
Greed or convergence?
rapprochement Describes the strength of the individual interaction between a binding site and its target.
Greed Describes the combined force of multiple interactions.
Thus, a nanoparticle carrying repeated copies of the antigen can achieve a high degree of affinity by engaging multiple binding sites on the B cell simultaneously. New studies suggest that this overall “grip” could influence which B cells gain an advantage during vaccination.
What have the researchers changed?
The Scripps research team created six types of nanoparticles for vaccines with different levels of repeatability. The most frequent nanoparticles carried 60 functional attachment points while the least had none.
Next, the researchers vaccinated mice whose B cells had been modified to recognize the specific attachment point for the nanoparticles.
In the first study, greater replication led to a longer-lasting immune response, including increased production and persistence of memory B cells, long-lived plasma cells and antibodies in the bloodstream.
The researchers also tested the effect of changing the strength of individual attachment points. This affected many immune responses as well, but repetition had a stronger effect overall.
The second study looked inward Germ centersThese are specialized areas where activated B cells compete, proliferate, and mature.
There, B cells that recognized the highly repetitive nanoparticles were preferentially able to mature compared to B cells exposed to the less repetitive nanoparticles. Stronger individual binding also improved B-cell success, but not as much as increased replication.
“So, the higher overall binding strength allowed B cells targeting this attachment point to better compete with other B cells, which is really exciting,” said Christopher Cottrell, author of both studies.
Why does early drug discovery matter?
Although this is vaccine research and not traditional small molecule drug discovery, this work illustrates an increasingly important principle in biomedical research: What a therapeutic molecule does depends not only on what it binds to, but on how that interaction is presented.
The researchers deliberately varied the number and strength of attachment points on the vaccine nanoparticles while keeping other properties, including particle size, constant. This allowed them to investigate how different aspects of binding affect the immune response.
For vaccine developers, this makes nanoparticle structure another potential design parameter besides the antigen itself, dose, formulation, and delivery system.
This may be particularly important for HIV because B cells capable of developing into neutralizing cells to produce antibodies on a large scale may be rare. Therefore, a successful vaccine may need to do more than activate these cells. They may need to help them compete successfully against other B cells.
How does this fit into what’s actually happening in the field?
The business is based on a broader strategy known as Germline targetingwhich aims to activate rare B cells capable of developing into neutralizing cells to produce antibodies on a large scale.
This approach has become a major focus of HIV vaccine research because conventional vaccination has had difficulties in reliably generating bnAbs.
Previous work by William Schiff and colleagues has shown that a nanoparticle-based vaccination strategy can produce mature, functional, broadly neutralizing antibodies capable of blocking multiple strains of HIV in non-human primates. The researchers believed that the nanoparticles used during the final vaccination were an important part of this success.
New studies look into why this happens.
“We’re trying to use everything we can in terms of vaccine design to get the strongest possible immune responses to stop HIV,” said Schiff, a senior author on both studies. “Both papers show that nanoparticles with higher overall binding strength lead to stronger immune responses at essentially every stage of the overall response. This makes overall binding strength a promising aspect to explore for making better vaccines.”
The latest results therefore represent not so much a new trend as an additional layer of precision in an already highly engineered field.
Key takeaways
- More replicated nanoparticles produced more sustained responses. The mice developed greater numbers of memory B cells, long-lived plasma cells, and circulating antibodies.
- Structure is important, not just quantity. The researchers found that the repeated order of binding sites was important rather than simply increasing the total number of catalytic sites.
- Competition between B cells is central. Highly replicating nanoparticles gave the desired precursor B cells an advantage within germinal centers, where B cells compete and mature.
- The results can help explain the translational challenge. Vaccine designs that perform well in simplified animal models may behave differently when faced with the more diverse B cell populations found in humans.
What does it mean for researchers?
Perhaps the most important finding of the researchers is this Competition between B cells changes the outcome.
When the researchers reduced the number of competing progenitor B cells in their mouse model, the advantage created by the larger nanoparticle frequency disappeared.
This could help explain why some vaccine designs performed well in early preclinical studies, but then struggled in humans. Simplified animal models may have less competition between B cell populations than occurs in humans.
For researchers, the implication is that vaccine candidates may need to be evaluated in models that better reflect the diversity and competition of the human immune system.
It also reinforces the idea that nanoparticle design can be used to effectively shape the immune response rather than simply deliver antigen.
What will happen next?
A key question is whether the results translate beyond these engineered mouse models.
Further studies will need to determine whether increased appetite produces similar B cell and antibody responses in more representative animal models, and eventually in humans.
The research doesn’t immediately bring an HIV vaccine closer to the clinic, but it provides another engineering “connection” for researchers to fine-tune as they work toward the much more difficult goal of generating broadly neutralizing antibodies that persist.
